Table 1 Sociodemographic, disease and treatment characteristics for participants who had and had not been invited to take part in a clinical trial
From: Access to clinical trials among oncology patients: results of a cross sectional survey
Have you been asked to take part in a clinical trial? | ||||
|---|---|---|---|---|
Variable | Category | Yes (n = 146) | No (n = 237) | Chi-square p-value |
Centre | 1 | 74 (49%) | 78 (51%) | 0.0005 |
2 | 28 (25%) | 83 (75%) | ||
3 | 44 (37%) | 76 (63%) | ||
Age | Less than 55 | 36 (34%) | 69 (66%) | 0.2089 |
55 to 74 | 90 (41%) | 127 (59%) | ||
75 and over | 18 (31%) | 41 (69%) | ||
Gender | Male | 59 (41%) | 84 (59%) | 0.3290 |
Female | 87 (36%) | 153 (64%) | ||
Aboriginal and/ or Torres Strait Islander | Non indigenous | 140 (37%) | 234 (63%) | 0.3701* |
Indigenous | 3 (60%) | 2 (40%) | ||
Marital | Married/living with partner | 92 (38%) | 147 (62%) | 0.7937 |
Single/divorced/separated/widowed | 52 (37%) | 88 (63%) | ||
Education | High school or less | 76 (39%) | 117 (61%) | 0.5317 |
University or vocational | 63 (36%) | 111 (64%) | ||
Country of birth | Australia | 105 (39%) | 167 (61%) | 0.6075 |
Other | 39 (36%) | 70 (64%) | ||
Health insured | Yes | 65 (44%) | 82 (56%) | 0.0332 |
No | 77 (33%) | 154 (67%) | ||
Concession card | Yes | 86 (37%) | 147 (63%) | 0.7000 |
No | 56 (39%) | 88 (61%) | ||
Smoking status | Current smoker | 16 (37%) | 27 (63%) | 0.9513 |
Former smoker | 65 (37%) | 110 (63%) | ||
Never smoked | 62 (39%) | 98 (61%) | ||
Location of residence | City/inner regional | 119 (38%) | 192 (62%) | 0.9282 |
Outer regional/remote | 26 (38%) | 43 (62%) | ||
Living arrangements | With others | 110 (37%) | 184 (63%) | 0.7784 |
Alone | 34 (39%) | 53 (61%) | ||
Employment | Full-time | 26 (42%) | 36 (58%) | 0.1934 |
Part-time | 15 (27%) | 40 (73%) | ||
All others | 103 (39%) | 159 (61%) | ||
Time since diagnosis | 12 m or less | 51 (31%) | 115 (69%) | 0.0029 |
13 to 24 m | 38 (54%) | 32 (46%) | ||
Over 24 m | 57 (40%) | 86 (60%) | ||
Surgery | No | 39 (41%) | 55 (59%) | 0.4808 |
Yes | 107 (37%) | 179 (63%) | ||
Chemotherapy | No | 25 (28%) | 64 (72%) | 0.0286 |
Yes | 118 (41%) | 170 (59%) | ||
Radiotherapy | No | 45 (34%) | 88 (66%) | 0.4610 |
Yes | 83 (38%) | 137 (62%) | ||
Hormone therapy | No | 92 (37%) | 157 (63%) | 0.6777 |
Yes | 36 (35%) | 68 (65%) | ||
Biological therapy | No | 107 (34%) | 205 (66%) | 0.0341 |
Yes | 21 (51%) | 20 (49%) | ||
Cancer stage at diagnosis | Early | 58 (32%) | 124 (68%) | 0.4376 |
Not applicable / Do not know | 9 (45%) | 11 (55%) | ||
Progressed/advanced | 21 (37%) | 36 (63%) | ||
Remission: | Do not know | 20 (29%) | 48 (71%) | 0.0306 |
In remission | 24 (30%) | 57 (70%) | ||
Not in remission | 66 (44%) | 83 (56%) | ||
Cancer type | Haematological/blood cancer | 5 (63%) | 3 (38%) | 0.3362 |
Breast | 52 (33%) | 108 (68%) | ||
Colorectal | 21 (38%) | 35 (63%) | ||
Prostate | 11 (33%) | 22 (67%) | ||
Lung | 13 (42%) | 18 (58%) | ||
Melanoma | 7 (50%) | 7 (50%) | ||
More than one type or other | 33 (45%) | 41 (55%) | ||
Reason for visit: combined | To discuss treatment | 20 (37%) | 34 (63%) | 0.9153 |
To receive treatment/check-up during treatment | 60 (38%) | 99 (62%) | ||
Check-up after treatment/other | 65 (40%) | 99 (60%) | ||